Clinical Trial Search

Primary: Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12…

Primary: Change in Reflux Disease Questionnaire Scores Administered at Baseline and 6 Weeks After Each Intervention — -1.2397; 0.0869 scores on a scale — p=0.0002

Primary: CLINICAL OUTCOME OF FEEDING SUCCESS — 33; 44 percentage of participants — p=0.28

Primary: Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment — -3.44 Days per week with symptoms

Primary: Patient's Assessment of General Well-being During the Last 24 Hours (Diaries; ReQuest™ in Practice) — 5.31; 4.60; 3.67; 2.95 Units on a scale

Primary: The Number of Patients With Complete Resolution of Heartburn by Week 4 — 272; 302; 278 participants — p=<0.05

Primary: Number of Refluxes — 0.48; 0.97 number of refluxes

Primary: Number of Participants That Had Desaturation Episodes of SpO2 <90% — 0; 3; 26; 27 Participants

Primary: Epidemiologic Factors Associated With Prevalent Reflux Disease. — 17.6 percentage of participants with GERD

Primary: Elimination of Moderate-severe Regurgitation at 6 Months — 10; 42 Participants

Primary: Number of Impedance Episodes Following PPI and Placebo — 47; 53 number of episodes

Primary: Presence of Reflux in Patients With Polyposis — 15 participants

Primary: Completion Rate — 39 Participants

Primary: Number of Subjects Reporting Treatment Emergent Adverse Events (TEAEs) — 12; 5; 21; 11 Participants

Primary: STAGE A1 - Number of Dose Limiting Toxicities for M6620 (Berzosertib) Administered Concomitantly With Radiotherapy (RT) in the Palliative Treatment of Oesophageal…